UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ | --- | --- | |----------------------------------------------------------------------------------------------------------------------|---- ...

Targeted chemotherapy delivery via TAMP is currently being evaluated in an ongoing Phase III clinical trial in LAPC "These important foundational studies highlight the potential for a meaningful advancement in the standard of care for cancer treatment, with less toxicity and improved outcomes," said Hassan Hatoum, MD. "These clinical data support that TAMP has the potential to extend OS compared to systemic chemotherapy in difficult-to-treat solid tumors and provide a paradigm-shifting treatment option for ...

LOS ALTOS, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced acceptance for publication in an international peer-reviewed journal, The Oncologist. The manuscript is titled, "Treatment of Locally Advanced Pancreatic Cancer (LAPC) Using Localized Trans-Arterial Micro Perfusion (TAMP™) of Gemcitabine: Combined Anal ...

Ramtin Agah, Chief Medical Officer and Founder of RenovoRx states, "These important studies investigate clinical outcomes along with procedural variables that may impact those clinical outcomes." The Oncologist is an international peer-reviewed Journal for the practicing oncologists and hematologists. It is dedicated to translating the latest research developments into the best multidimensional care for cancer patients and is committed to helping physicians excel in this ever-expanding environment through t ...

LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the University of Nebraska Medical Center (UNMC) is now enrolling patients with Locally Advanced Pancreatic Cancer (LAPC) in the Company's ongoing pivotal Phase III TIGeR-PaC clinical trial. The TIGeR-PaC study is using RenovoRx's patented TAMP (Tr ...

The TIGeR-PaC study is using RenovoRx's patented TAMP (Trans-Arterial Micro-Perfusion) therapy platform to evaluate its RenovoGem investigational drug-device combination product. RenovoGem utilizes pressuremediated delivery of chemotherapy across the arterial wall to bathe tumor tissue. The study is comparing treatment with TAMP to the current standard-of-care (systemic intravenous chemotherapy). "We are proud to partner with Dr. Klute and her team in our Phase III TIGeR-PaC trial," said Leesa Gentry, Chief ...

Company Overview - RenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug delivery platform aimed at improving therapeutic outcomes for cancer patients [4] - The company's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery to directly target tumors while potentially minimizing toxicities compared to systemic intravenous therapy [4] - RenovoRx's lead product candidate, RenovoGem™, is a novel oncology drug-device combination product currently in Phase III clinical development for the treatment of locally advanced pancreatic cancer (LPAC) [4][5] Leadership and Strategy - Ryan Witt has been appointed as Senior Vice President, Head of Corporate Strategy and Partnerships, bringing extensive corporate strategy and operational experience from roles at Spinogenix, Immix Biopharma, StartX, and UCLA Biodesign [1][7][9] - Mr Witt's leadership will focus on advancing RenovoRx's pivotal Phase III clinical trial, expanding development opportunities into additional cancers, and exploring new commercial business development opportunities with the company's therapeutic technology [9] - The appointment highlights RenovoRx's commitment to exploring and executing on clinical and commercial business development opportunities for its RenovoGem™ investigational combination product and other therapeutic agents [5] Technology and Pipeline - RenovoRx's TAMP™ therapy platform offers the potential for increased safety, tolerance, and improved efficacy in targeted cancer treatment [4] - RenovoGem™ is being investigated under a US investigational new drug application regulated by the FDA's 21 CFR 312 pathway for the treatment of LPAC [4] - The company is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care [6] Industry and Partnerships - Mr Witt has a strong track record in leading corporate strategy and managing partnerships across top 25 global biopharma companies [1] - He serves on Biocom's Capital Development Committee, which hosts Partnering Days with large multinational healthcare companies including Baxter, Bristol Myers Squibb, Daiichi-Sankyo, GSK, Novo Nordisk, and Eli Lilly [1] - RenovoRx has collaborated with Imugene and has clinical data delivering gemcitabine with its drug-delivery platform, demonstrating the potential of its technology [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR (Former name, former address and former fiscal year, if changed since last report) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ COMMISSION FILE NUMBER: 001-40738 RENOVORX, INC. (Exac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______to ______ Commission File Number: 001-40738 RENOVORX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiza ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ________ TO ________ COMMISSION FILE NUMBER: 001-40738 RENOVORX, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 27-1448452 (State or other jurisdiction of incorporation or organization) 4546 El Camino Real, Suite B1 Los Altos, California 94022 (Address of principal executive ...